Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
- Conditions
- SyncopeCryptogenic StrokeTachyarrhythmiaAtrial Fibrillation (AF)
- Registration Number
- NCT04025710
- Lead Sponsor
- Biotronik SE & Co. KG
- Brief Summary
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III and BIOMONITOR IIIm that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Furthermore, this study will also provide additional data as required by regulatory authorities outside of the CE-region.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 167
- Patient is at high risk of developing a clinically important cardiac arrhythmia; or
- Patient is undergoing investigation for symptoms such as palpitations, pre- syncope or syncope, that are suggestive of an underlying cardiac arrhythmia; or
- Patient is undergoing investigation for the detection of atrial fibrillation following cryptogenic stroke; or
- Patient is planned for AF ablative procedure or has already undergone an AF ablative procedure.
- Patient is able to understand the nature of the study and able to provide written informed consent.
- Patient is willing and able to perform all follow-up visits at the investigational site.
- Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home Monitoring concept.
- Patient is implanted with an ICD or pacemaker.
- Patient is pregnant or breast-feeding.
- Patient is less than 18 years old.
- Patient's life-expectancy is less than 12 months.
- Patient is participating in another interventional clinical investigation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method SADE-free Rate Until the 3-month Follow-up 3 months SADE-free rate related to BIOMONITOR III and BIOMONITOR IIIm including incision and insertion tool set until 3-month follow-up
- Secondary Outcome Measures
Name Time Method Noise Burden 10 days to 4 weeks after insertion; 3-months The secondary endpoint 2 evaluates the noise burden at the 1st follow-up and at 3-month follow-up by retrieving the percentage of noise via the programmer.
R-wave Amplitude 10 days to 4 weeks after insertion; 3-months The secondary endpoint 1 evaluates the R-wave amplitude at the 1st follow-up and at 3-month follow-up by measuring both, the lowest and the highest amplitude value via the programmer.
SADE-free Rate Until the 12-month Follow-up 12-months The secondary endpoint 4 is the SADE-free rate related to the BIOMONITOR III and BIOMONITOR IIIm 12 months after insertion.
Assessment of P-wave Visibility 10 days to 4 weeks after insertion; 3-months The secondary endpoint 3 evaluates the P-wave visibility at 1st, 3- and 12-month follow-up. The investigator will evaluate whether P-waves can be recognized in the stored sECGs showing sinus rhythm. The number of heart cycles and observed P-waves which can undoubtly be identified in ECGs will be assessed by the investigator.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (27)
GenesisCare Wesley
🇦🇺Auchenflower, Australia
GenesisCare Bundaberg
🇦🇺Bundaberg, Australia
GenesisCare Doncaster
🇦🇺Doncaster East, Australia
Canberra Heart Rhythm Clinic
🇦🇺Garran, Australia
Prince of Wales Hospital
🇦🇺Randwick, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Kepler Universitätsklinikum
🇦🇹Linz, Austria
Klinikum Wels-Grieskirchen
🇦🇹Wels, Austria
Allgemeines Krankenhaus der Stadt Wien (AKH)
🇦🇹Wien, Austria
Regionshospitalet Viborg
🇩🇰Viborg, Denmark
Scroll for more (17 remaining)GenesisCare Wesley🇦🇺Auchenflower, Australia